Meaningful vision gains of >10 letters were observed after a single injection in the Asian cohort, with continued improvement through 24 weeks 15 Final results of the APEX study in MESI. Includes patients in the per protocol set that completed the Week 4 visit and met all the eligibility criteria. US: Excludes one patient in the 5 mg dose that discontinued treatment before Week 4, and one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion). One patient in the 10 mg dose level discontinued after Week 12 due to recurrent uveitis flare-up. Asian cohort: excludes one patient with a significant epiretinal membrane at baseline (exclusion criterion). One patient discontinued after Week 12 due to a spinal fracture. 0 5 10 15 20 0 4 8 12 16 20 24 Mean ETDRS letters Weeks U.S. 2.5 mg U.S. 5 mg U.S. 10 mg Asia Pooled 2.5 mg 13 13 13 13 13 13 13 12 5 mg 13 13 13 13 13 13 13 13 10 mg 13 13 13 13 13 12 12 12 Pooled 12 12 12 12 12 11 11 11 U.S. Asia Mean Change in BCVA Sample Size